Mean central retinal thickness (CRT) change at 6 months in microns (lower value is better) · people with BRVO
1 finding from 1 review
Adverse outcomes at any time point · people with BRVO
It is very uncertain whether anti‐VEGF changes adverse outcomes at any time point compared with laser (very low certainty).
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · CNV in people with pathologic myopia
1 finding from 1 review
Gain 3+ lines of visual acuity at 1 year · CNV in people with pathologic myopia
Anti‐VEGF probably leads to higher gain 3+ lines of visual acuity at 1 year compared with control (moderate certainty).
1 finding from 1 review
Change in central macular thickness at 1 year · CNV in people with pathologic myopia
1 finding from 1 review
CNV angiographic closure at 1 year · CNV in people with pathologic myopia
Anti‐VEGF showed no clear difference in CNV angiographic closure at 1 year compared with control (low certainty).
1 finding from 1 review
Serious systemic adverse events · CNV in people with pathologic myopia
It is very uncertain whether anti‐VEGF changes systemic serious adverse events compared with control (very low certainty).
1 finding from 1 review
Adverse events (ocular problems) · CNV in people with pathologic myopia
It is very uncertain whether anti‐VEGF changes ocular adverse events compared with control (very low certainty).
1 finding from 1 review
Quality of life · CNV in people with pathologic myopia
1 finding from 1 review
Contrast sensitivity (log contrast threshold) Measured using a Pelli‐Robson chart. Higher scores represent better contrast sensitivity. · people with neovascular AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
New vessel growth Measured using fluorescein angiography or fundus photographs · people with neovascular AMD
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Quality of life · people with neovascular AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse outcome · people with neovascular AMD
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with neovascular AMD
Radiotherapy combined with anti‐VEGF probably leads to higher loss of 3 or more lines of best‐corrected visual acuity Measured… compared with anti‐VEGF alone (moderate certainty).
1 finding from 1 review
RR 2.11 [1.4, 3.17]
Studies not reported
Moderate
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · people with neovascular AMD
Radiotherapy combined with anti‐VEGF showed no clear difference in change in best corrected visual acuity (logMAR units) Measured using… compared with anti‐VEGF alone (low certainty).
1 finding from 1 review
mean difference 0.1
Studies not reported
Low
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with centre‐involving diabetic macular oedema
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Improvement in central macular thickness on OCT · adults with centre‐involving diabetic macular oedema
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Significant intraocular inflammation at · adults with centre‐involving diabetic macular oedema
It is very uncertain whether summary of findings: intravitreal anti‐VEGF plus intravitreal steroid changes significant intraocular inflammation at compared with intravitreal anti‐VEGF (very low certainty).
1 finding from 1 review
Development of cataract at · adults with centre‐involving diabetic macular oedema
Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid probably leads to higher development of cataract at compared with intravitreal anti‐VEGF (moderate certainty).
1 finding from 1 review
Raised Intraocular Pressure at · adults with centre‐involving diabetic macular oedema
Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid probably leads to higher raised intraocular pressure at compared with intravitreal anti‐VEGF (moderate certainty).
1 finding from 1 review